347 related articles for article (PubMed ID: 32603772)
1. Targeting inflammation and cytokine storm in COVID-19.
Huang Q; Wu X; Zheng X; Luo S; Xu S; Weng J
Pharmacol Res; 2020 Sep; 159():105051. PubMed ID: 32603772
[No Abstract] [Full Text] [Related]
2. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.
Shah A
Front Immunol; 2020; 11():1021. PubMed ID: 32574259
[No Abstract] [Full Text] [Related]
3. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
[TBL] [Abstract][Full Text] [Related]
4. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
5. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.
Saini KS; Lanza C; Romano M; de Azambuja E; Cortes J; de Las Heras B; de Castro J; Lamba Saini M; Loibl S; Curigliano G; Twelves C; Leone M; Patnaik MM
Br J Cancer; 2020 Sep; 123(5):694-697. PubMed ID: 32572174
[TBL] [Abstract][Full Text] [Related]
6. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
7. Severe COVID-19: NLRP3 Inflammasome Dysregulated.
van den Berg DF; Te Velde AA
Front Immunol; 2020; 11():1580. PubMed ID: 32670297
[TBL] [Abstract][Full Text] [Related]
8. Treating COVID-19 with colchicine in community healthcare setting.
Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
[No Abstract] [Full Text] [Related]
9. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
Bertocchi I; Foglietta F; Collotta D; Eva C; Brancaleone V; Thiemermann C; Collino M
Br J Pharmacol; 2020 Nov; 177(21):4921-4930. PubMed ID: 32776354
[TBL] [Abstract][Full Text] [Related]
10. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Quartuccio L; Semerano L; Benucci M; Boissier MC; De Vita S
Joint Bone Spine; 2020 May; 87(3):191-193. PubMed ID: 32321634
[No Abstract] [Full Text] [Related]
11. COVID-19: consider cytokine storm syndromes and immunosuppression.
Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
[No Abstract] [Full Text] [Related]
12. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.
Ratajczak MZ; Kucia M
Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300
[TBL] [Abstract][Full Text] [Related]
13. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
14. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
Front Immunol; 2020; 11():2056. PubMed ID: 32973814
[TBL] [Abstract][Full Text] [Related]
15. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.
Soni S; Dyck JRB
Can J Cardiol; 2020 Oct; 36(10):1691.e3. PubMed ID: 32717278
[No Abstract] [Full Text] [Related]
16. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.
DiNicolantonio JJ; Barroso J; McCarty M
Open Heart; 2020 Sep; 7(2):. PubMed ID: 32895293
[No Abstract] [Full Text] [Related]
17. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
Abdulrab S; Al-Maweri S; Halboub E
Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
[No Abstract] [Full Text] [Related]
18. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.
Sarma P; Prajapat M; Avti P; Kaur H; Kumar S; Medhi B
Indian J Pharmacol; 2020; 52(1):1-5. PubMed ID: 32201439
[No Abstract] [Full Text] [Related]
19. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
20. East meets West in COVID-19 therapeutics.
Wang S; Zeng X; Wang Y; Zhao Y; Chen W; Chen YZ
Pharmacol Res; 2020 Sep; 159():105008. PubMed ID: 32531323
[No Abstract] [Full Text] [Related]
[Next] [New Search]
